( OTCQB: BIXT) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, ...

Bioxytran, Inc. (OTCQB: BIXT) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization ...

RWD and RWE are reshaping the design of clinical trials, making them smarter, faster, and more efficient. Read more here: ...

For people living with atopic dermatitis, the real test of any new therapy is not what it can do in a few months, but whether it can keep angry, inflamed skin quiet over the long haul. Nektar ...

February 2026 is shaping up to be a monumental month for Xbox enthusiasts, with a diverse slate of titles arriving on both ...

Over time, places like Monte Carlo and Las Vegas turned gambling into a global industry, packed with bright lights, high stakes, and non-stop traffic. Casinos like the Bellagio, MGM Grand, and Marina ...

Bioxytran has reported positive results from its completed phase 2 trial of ProLectin‑M, showing rapid and sustained viral clearance in subjects with laboratory‑confirmed acute viral infection. The ...

FDA proposes MRD-negative and complete response endpoints to fast-track multiple myeloma drug approvals, pushing deeper molecular results over ORR.

This engagement begins as a defined pilot, with a clear path to expand into a multi-study commercial relationship based on results. For Lunai, this is the kind of near-term work that can translate ...

Most return-to-office mandates aren’t solving a collaboration problem. They’re solving an assessment problem that physical ...

DARE to PLAY™ represents the first and only evidence-backed sildenafil cream formulation for women. Its commercial availability through a 503B outsourcing facility will mark the first time a topical ...

Obexelimab met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo over weeks ...